Pharma Leader Bill Anderson Makes Rapid Exit From Roche
Was He Passed Over For CEO Role?
Executive Summary
Bill Anderson is leaving Roche after leading its pharma division through the loss of three oncology blockbusters and the launch of a new generation of blood cancer therapies.
You may also be interested in...
Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.
Reunited At Last At J.P. Morgan; Will The Sparks Still Fly?
The annual J.P. Morgan Healthcare conference will return to San Francisco on 9 January after being held virtually for two years.
Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.